fth1 sirna (Santa Cruz Biotechnology)
Structured Review

Fth1 Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fth1 sirna/product/Santa Cruz Biotechnology
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Anticancer activity of RM-3-22: a TAZQ-based hydroxamic acid derivative targeting NSCLC in vitro and in vivo"
Article Title: Anticancer activity of RM-3-22: a TAZQ-based hydroxamic acid derivative targeting NSCLC in vitro and in vivo
Journal: Frontiers in Pharmacology
doi: 10.3389/fphar.2025.1544666
Figure Legend Snippet: RM-3-22 induces the upregulation of FTH1, a tumor suppressor of NSCLC, which is positively correlated with apoptosis and autophagy pathway. (A) Western blot analysis shows the increased expression of FTH1. Data represent the mean ± SD of three independent experiments (one-way ANOVA; *p < 0.05, **p < 0.01, and ***p < 0.001). (B) qRT-PCR of FTH1 shows an increase in the mRNA level due to RM-3-22 exposure, both in a concentration-dependent manner. Data represent the mean ± SD of three independent experiments (one-way ANOVA; *p < 0.05, **p < 0.01, and ***p < 0.001). (C) Protein–ligand interaction diagram; (a) crystal structure of FTH-1 (PDB: 6J4A) interacting with ligand RM-3-22. (b) 2D molecular interaction of FTH-1 with RM22, docked using AutoDock Vina. Projected bonds are shown. Docking score -8.1. (D) Kaplan–Meier plotter survival analysis for patients with expression of FTH1. Survival analysis was performed in KM plotter using publicly available microarray data that are available within the database. A log-rank p-value ≤0.05 was considered significant. HR, hazard ratio. The red curve represents high expression, and the black curve represents low expression. OS)of the patients increases with high expression of FTH1 in lung cancer. (E) The FTH1 transcript level seems to decrease slightly during LUAD and lung squamous cell carcinoma (LUSC) progression in the patients (UALCAN database, TGCA sample), which indicates the tumor-suppressive nature of FTH1 in lung cancer. (F) PPI network of FTH1, autophagy, and apoptosis-related proteins constructed in Cytoscape based on interaction information derived from the STRING database. The network contains 10 nodes (proteins) and 37 edges (interactions). PPI showed the interaction of FTH1 with SQSTM1 and MAP1LC3B and FTH1 with CYCS (cytochrome C). For this specific interaction, edge color is specified as red. (G) Gene correlation analysis exhibited a positive correlation of FTH1 with MAP1LC3B and pro-apoptotic protein BAX and a negative correlation with anti-apoptotic protein Bcl2 at a significance level (*p < 0.05) (data from TCGA, cbiojune.en). (H) FTH1 knockdown by siRNA in A549 cells. Data represent the mean ± SD of three independent experiments (t-test; *p < 0.05, **p < 0.01, and ***p < 0.001). (I) Migration efficiency was higher in FTH1-downregulated cells treated with RM-3-22 compared to normal A549 cells solely treated with RM-3-22. (J) FTH1 knockdown led to the reversal of nuclear fragmentation, which is accompanied by RM-3-22. (K) Schematic representation showing the regulation of FTH1 by RM-3-22.
Techniques Used: Western Blot, Expressing, Quantitative RT-PCR, Concentration Assay, Microarray, Construct, Derivative Assay, Knockdown, Migration
Figure Legend Snippet: RM-3-22 suppresses tumor growth and induces autophagy, apoptosis, cell-cycle arrest, and FTH1 upregulation. (A) Tumor volume reduced in the treated group after treatment of RM-3-22 (DC, disease control; TG, treated group). Tumor sizes were measured every 2 days using the formula tumor volume= (width) 2 x length/2. (B) Representative photomicrographs of hematoxylin and eosin staining showed disrupted tissue structure and damaged nuclei in RM-3-22-treated tissue. Scale bar = 100 μm (the box indicates the close-up view of disrupted structures; scale bar = 50 μm). (C) IHC of MAP1LC3B protein expression from DC and TG of mice. Scale bar = 100 μm (the box indicates the close-up view; scale bar = 50 μm). Data represent the mean ± SD of three independent experiments (t-test; *p < 0.05, **p < 0.01, and ***p < 0.001). (D) Western blot analysis was used to calculate the expression levels of MAP1LC3B, FTH1, cyclin B 1, and PARP-1 in tumor samples. Data represent the mean ± SD of three independent experiments (*p < 0.05, **p < 0.01, and ***p < 0.001). Schematic representation is presented in (E) .
Techniques Used: Control, Staining, Expressing, Western Blot
Figure Legend Snippet: Summary of the mechanism of action after RM-3-22 treatment. The diagram indicates that RM-3-22 is responsible for the inhibition of the PI3K/Akt/mTOR pathway, which leads to the activation of the autophagy pathway, marked by the induction of regulatory makers of autophagy, MAP1LC3B II and Beclin1, and also the degradation of p62. The induction of the autophagy pathway further induces the apoptosis pathway, confirmed by the translocation of BAX from the cytosol to the nucleus, and subsequently the cleavage of PARP-1 and caspase 3. RM-3-22-induced autophagy is further responsible for the G2/M cellcycle arrest, and this is confirmed by the destruction of cyclin B1 and CDC2 in a dose-dependent way. Apart from that, RM-3-22 activates FTH1-related tumor suppression in NSCLC.
Techniques Used: Inhibition, Activation Assay, Translocation Assay

